Model-based evaluation of pulmonary pharmacokinetics in asthmatic and COPD patients after oral olodaterol inhalation.
暂无分享,去创建一个
Alexander Staab | Charlotte Kloft | Christina Kunz | C. Kloft | C. Kunz | A. Staab | Benjamin Weber | Jens Markus Borghardt | Benjamin Weber | J. M. Borghardt
[1] C. Kim,et al. Regional deposition of inhaled particles in human lungs: comparison between men and women. , 1998, Journal of applied physiology.
[2] P. Daley-Yates. Inhaled corticosteroids: potency, dose equivalence and therapeutic index , 2015, British journal of clinical pharmacology.
[3] Chapter 7 – Airway Remodeling , 2009 .
[4] R. Pauwels,et al. The inhalation device influences lung deposition and bronchodilating effect of terbutaline. , 1996, American journal of respiratory and critical care medicine.
[5] L. Borgström,et al. Do airway clearance mechanisms influence the local and systemic effects of inhaled corticosteroids? , 2008, Pulmonary pharmacology & therapeutics.
[6] G. Pairaudeau,et al. Discovery of AZD3199, An Inhaled Ultralong Acting β2 Receptor Agonist with Rapid Onset of Action. , 2014, ACS medicinal chemistry letters.
[7] R. Crystal,et al. Cigarette smoking reprograms apical junctional complex molecular architecture in the human airway epithelium in vivo , 2011, Cellular and Molecular Life Sciences.
[8] M. Sakagami. Insulin Disposition in the Lung Following Oral Inhalation in Humans , 2004, Clinical pharmacokinetics.
[9] R. Woessner,et al. Systemic pharmacokinetics of indacaterol, an inhaled once-daily long-acting beta2-agonist, in different ethnic populations. , 2012, International journal of clinical pharmacology and therapeutics.
[10] P. Casarosa,et al. Functional and Biochemical Rationales for the 24-Hour-Long Duration of Action of Olodaterol , 2011, Journal of Pharmacology and Experimental Therapeutics.
[11] A. James,et al. Clinical relevance of airway remodelling in airway diseases , 2007, European Respiratory Journal.
[12] O. Usmani,et al. Assessing and treating small airways disease in asthma and chronic obstructive pulmonary disease , 2012, Annals of medicine.
[13] Karline Soetaert,et al. Solving Differential Equations in R: Package deSolve , 2010 .
[14] C D COOK,et al. Relation between mechanics of respiration, lung size and body size from birth to young adulthood. , 1958, Journal of applied physiology.
[15] W. Foster,et al. Measurement of tracheal and bronchial mucus velocities in man: relation to lung clearance. , 1980, Journal of applied physiology: respiratory, environmental and exercise physiology.
[16] Peter Brand,et al. Higher lung deposition with Respimat® Soft Mist™ Inhaler than HFA-MDI in COPD patients with poor technique , 2008, International journal of chronic obstructive pulmonary disease.
[17] Cockcroft Dw,et al. Prediction of Creatinine Clearance from Serum Creatinine , 1976 .
[18] J. Walsh,et al. Pharmacokinetics and pharmacodynamics of inhaled versus intravenous morphine in healthy volunteers. , 2000, Anesthesiology.
[19] C. Kunz,et al. Pharmacokinetics and safety of olodaterol administered with the Respimat Soft Mist inhaler in subjects with impaired hepatic or renal function , 2016, International journal of chronic obstructive pulmonary disease.
[20] R. Pauwels,et al. Variability in lung deposition of inhaled drug, within and between asthmatic patients, with a pMDI and a dry powder inhaler, Turbuhaler. , 2000, International journal of pharmaceutics.
[21] Margareta Hammarlund-Udenaes,et al. Development of a Novel Lung Slice Methodology for Profiling of Inhaled Compounds. , 2016, Journal of pharmaceutical sciences.
[22] F. Martinez,et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.
[23] Adnan Custovic,et al. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study , 2000, The Lancet.
[24] C. Hallett. Corticosteroid treatment of asthma: now at the crossroads. , 1999, Respiratory medicine.
[25] Michael Looby,et al. Determination of the pharmacokinetics of glycopyrronium in the lung using a population pharmacokinetic modelling approach. , 2013, British journal of clinical pharmacology.
[26] O. Usmani,et al. Regional Lung Deposition and Bronchodilator Response as a Function of β2-Agonist Particle Size , 2005 .
[27] K. Aoshiba,et al. Differences in airway remodeling between asthma and chronic obstructive pulmonary disease , 2004, Clinical reviews in allergy & immunology.
[28] W. Finlay,et al. In vitro intersubject and intrasubject deposition measurements in realistic mouth-throat geometries , 2004 .
[29] J. Lötvall,et al. Comparison of the bronchodilator and systemic effects of AZD3199, an inhaled ultra-long-acting β2-adrenoceptor agonist, with formoterol in patients with asthma , 2013, Therapeutic advances in respiratory disease.
[30] R J Keizer,et al. Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose , 2013, CPT: pharmacometrics & systems pharmacology.
[31] H. Möllmann,et al. Interpretation of absorption rate data for inhaled fluticasone propionate obtained in compartmental pharmacokinetic modeling. , 2005, International journal of clinical pharmacology and therapeutics.
[32] W. Hofmann,et al. Prediction of particle deposition in the human lung using realistic models of lung ventilation , 2006 .
[33] A. Mohammed,et al. The impact of ageing on the barriers to drug delivery. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[34] Alexander Staab,et al. Investigating pulmonary and systemic pharmacokinetics of inhaled olodaterol in healthy volunteers using a population pharmacokinetic approach. , 2016, British journal of clinical pharmacology.
[35] R. Kempsford,et al. Pharmacokinetics and pharmacodynamics of intravenous and inhaled fluticasone furoate in healthy Caucasian and East Asian subjects , 2014, British journal of clinical pharmacology.
[36] D. DeMeo,et al. Chapter 2 – Epidemiology , 2002 .
[37] R. Perry,et al. Interpretation of "24 Hour Lung Retention" in Studies of Mucociliary Clearance , 1988 .
[38] Chantal Darquenne,et al. Aerosol deposition in health and disease. , 2012, Journal of aerosol medicine and pulmonary drug delivery.
[39] K. Brown,et al. The pharmacokinetics of nedocromil sodium, a new drug for the treatment of reversible obstructive airways disease, in human volunteers and patients with reversible obstructive airways disease. , 1987, British journal of clinical pharmacology.
[40] P. Barnes,et al. The airway vasculature: recent advances and clinical implications , 2009, Thorax.